Expo attended by over 30,000 delegates from across the globe
CPhI India, P-MEC India and ICSE, the three-day pharma industry event, was recently held in Mumbai. The first day of the event witnessed over 1000 plus exhibitors from over 100 countries. The expo is likely to be attended by over 30,000 delegates from across the globe.
The event was inaugurated by Sudhanshu Pandey, Joint Secretary, Dept. of Commerce, Government of India. In his address, he said, “Platforms like these recognise people and motivate them to do better while continuing to inspire others. The last few years have been tough on the pharma sector due to various issues and challenges with regards to regulatory norms. But we must address these challenges in the right spirit. It’s a long way for the Indian pharma industry, but we are on the right track. India today boasts of world class facilities. The road may be tough but we have what it takes to get there.”
Pandey also shared some of the (Indian) government’s plans to boost the industry. He mentioned that the government is trying to make regulations more stringent and is also working on minimising/ simplifying the process. The government is trying to understand the industry issues and is willing to work on it. He pointed out that there has been a dip in India’s pharma exports and indicated that the government and the DGFT are finalising different policies to reverse this slide. He assured industry attendees that the government has allocated sufficient funds for resource deployment and creation of infrastructure in the current year and concluded that if these are utilised, more would be allocated by the Government.
Joji George, Managing Director, UBM India said, “Against the backdrop of India constantly seeking to match and surpass Western quality standards while maintaining lower manufacturing costs, at UBM, our objective for CPhI 2014 is to help elevate India as the global pharma destination by showcasing the unique positioning of the Indian pharma market and provide an optimum investment platform amidst its global counterparts.”
The event also saw the launch of a report titled, Pharma Insights: India 2015. One of the most startling trends to emerge from the report is that small and medium sized enterprises (SMEs) that have traditionally relied on the domestic market are now rapidly expanding and emerging as MNCs based on exports led growth strategies. For example, Galpha Laboratories, 66 per cent of sales this year were domestic, has seen exports expand by 400 per cent in the last year. Moreover, some of India’s biggest companies are also investing heavily in R&D programmes to safeguard against slower growth as a result of the patent cliff, this has increasingly been across new drug delivery systems, formulation and manufacturing technology, along with biosimilars.
Report highlights
CPhI India report forecasts new MNCs to emerge from India’s pharma SMEs and Japan and Africa as key export growth markets
Indian manufacturers are evolving up the value chain, concentrating on high-value, low volume work and shifting some R&D programmes to Western economies.
India’s biggest companies will see growth in CRAMS services for patented products as trust in regulatory and quality standards increases
India to increasingly become a hotbed of clinical trial supply and advanced development work
Biggest players to grow technology base through overseas acquisitions and partnering with big pharma for R&D
Expenditures on R&D by 30 of the top pharma companies in India rose by 19.7 per cent, with investments focused on novel drug delivery systems
Some of India’s biggest players are actively investing in R&D facilities abroad — Sun, Piramal, Lupin and Cipla
New chemical entities from India to emerge in the next few years. Cutting edge research is underway, including innovations in creating an oral dosage form of insulin
Huge future growth potential in Japan where Indian companies currently have limited presence, but there is predicted to be a rapidly rising use of generics
In 2015 a significant number Indian companies will enter the African market as growth is predicted at 25 per cent to 30 per cent by volume per year
Biologics and biosimilars to represent 15 per cent of Indian market value by 2020
India’s API producers have increasingly started to shift towards high value low volume work with complex chemistry and IP challenges.
Sudarshan Jain, Managing Director, Abbott Healthcare Solutions commented, “The Indian pharma sector is clearly growing, making significant contributions to the Indian economy and putting us on the global map. This sector is redefining itself by moving to ‘next practices’ from ‘best practices’. We see strong thrust in the manufacturing arena in line with our national priority of ‘Make in India’. Some of the entries for the award clearly reflect good work done by Indian pharma industry and augurs well for the industry.”
Devinder Pal, President, Catalyst Pharma Consult said, “One of the key challenges faced by the industry is to reclaim the enviable reputation it had earned, which has unfortunately got tarnished rather badly. Happily, the FDA administered jolts have done the trick, it has awakened the industry to the need of building quality culture and shunning complacency and jugaad.”
Dr Ajit Dangi, President and Chief Executive Officer, Danssen Consulting highlighted, “In CPhI/P- MEC , the key elements have always been innovation and excellence.
Organisations are increasingly focusing on 3 Ps – People, Planet and Profit and have started recruiting chief sustainability officers to give them competitive edge. The CPhI/ P-MEC event will provide good insight in to initiatives in this area.”
Technical sessions were organised on topics like advances in fluid bed processing and tablet coating technologies, quality by design, the UK generics market, Active Pharmaceutical Ingredient (API) and finished pharma product preparation, e Lab notebook and e MES- Future of pharma industry, innovation drives green growth: advanced flow reactor technology industrial production made real, improving quality and saving cost by lean materials handling and defining the future of digital advertising.
Another area that will transform over the coming years is biotech and biosimilars. The CPhI Pharma Insights: India report envisages further investment and expansion across this sector, predicting that by 2020, this part of the market will have risen up to around 15 per cent of total sales.
EP News Bureau – Mumbai
Quote Unquote
This time we have witnessed that the CPhI India has become a larger show in comparison to its previous editions. This might be because of the ‘Make in India’ campaign. After the launch of the campaign, we feel that the confidence level in the global market has increased. Many global pharma giants are coming up to make India a global hub for sourcing requirements. We conducted several meetings during the show with global as well as local clients. The only thing which I would like to point out to the organisers’ of the show is that they should think about changing the venue location because the issues related to the infrastructure is getting severe year after year.
– Chakravarthi AVPS, Chairman Indian Institute of Packaging and CEO and Managing Director, Ecobliss
This years’ event was excellent and there was no doubt about getting good responses from domestic as well as from the international markets.
This year we did good business with new customers. This platform creates a better opportunity to meet our old customers as well as create an avenue to meet prospective customers. I feel organisers should work on the infrastructure part.
– Pradeep M Tamhane, Managing Director, Wincoat Colours and Coatings
We realised that this year’s CPhI and P-Mech show had the maximum number of foreign visitors, particularly at our stallnearly one-third of the visitors were foreigners. We haven’t seen these many international visitors in the previous years. I think ‘Make in India’ campaign has caused the success of the show as the campaign has spread a message of good governance. People have started believing in the Indian companies and their capabilities.
– Suresh Pareek, Managing Director, Ideal Cures
CPhI and P-Mec are shows where we have been participating for many years now. However, I am not sure whether this kind of show is really meant for us or not. I suggest to the organisers to arrange a separate platform for us to understand the new technologies and better interactions options. For us this is more about the relationship building than anything else. We would like to know what plans do the organisers have for people like us. Separate sections like they have made it for bulk drugs and machineries? Also I believe they should have separate set of seminars and workshops here and engage people better. In fact I feel that the Interphex is a balanced show and there are all these opportunities.
– Christophe Boulanger, Managing Director, NNE Pharmaplan
Overall, this year’s event was good and saw a large number of customers from across the globe. However, I felt that the attendance from Middle East, Bangladesh and Nepal were less.
– Laxmikant Khaitan, Business Manager – Healthcare Packaging India
This time during the show we have received good responses, better than all the previous years. Also this year we managed to crack a business deal during the show.
– KVA Naidu, Cyklop Packaging
I personally feel the response to the exhibition was excellent. For us this time it resulted in big business. Also, we noticed that this year the maximum number of visitors were decision takers. We saw mixed representations from across the world.
– Ravi Sharma, Chief Executive Officer, Allpharm Technologies
During the first two day, we saw many visitors at our stall and received good responses. I noticed that nearly 80 per cent customers were from India and remaining were from Nepal, Bangladesh, Korea, Pakistan, Egypt, Iran and Turkey as well as from South East Asia. We launched one of our product here this time which we had launched almost three years back in China and received good response for it.
– Li Wei, Sales Manager, Truking Technology
Through associations, this year there were good turnout of buyers and customers for the show. We have seen large number of visitors from countries like Syria, Egypt and Jordan.
– Madan Mohan Singh, Director, Snowbell Machines
CPhI and P-Mec India edition is getting better year after year. Eight years back we had told the UBM to come to India and it will become a biggest show in the world and eventually did this happen. However, they should work on infrastructure as it is hardly worth it. Our recommendation to the Ministry of Commerce is to make a event venue to have a large venue to accommodate events like this.
– Ajit Singh, Chairman, ACG Worldwide
CPhI and P-Mec 2014 was a good show for us. This is a great platform for us to interact with our existing as well as prospective clients. Also, we have noticed that this year the footfall was good and received a good amount of business queries.
– Ken Fallu, Marketing and Product – Managing Director, Optel
EP News Bureau – Mumbai
